论文信息 - Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study - 字舞流文

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

M. Malim | A. Hayday | S. Irshad | B. North | J. Spicer | M. Harries | C. Graham | K. Doores | S. Kamdar | A. Laing | T. Tree | S. Papa | P. Fields | L. Monin | M. Muñoz-Ruiz | Duncan R. McKenzie | T. Hayday | Magdalene Joseph | Daniel Davies | Richard Davis | Yin Wu | J. Seow | F. Di Rosa | L. Dupont | A. Rigg | A. Montes | P. Patten | A. Swampillai | R. Graham | Thanussuyah Alaguthurai | I. Francos Quijorna | J. Vidler | Muhammad Khan | Irene del Molino del Barrio | Helen Kakkassery | C. Domingo-Vila | J. Cooper | E. Harvey-Jones | J. Eum | Shubhankar Sinha | Sultan Abdul-Jawad | S. Sinha | Charlotte O’Brien-Gore | Puay Ling Lee | M. Conde Poole | Jennifer Vidler | Shraddha Kamdar | Adam G. Laing | María Conde Poole | T. Alaguthurai

[1] Graham W. Taylor,et al. SARS-CoV-2 evolution during treatment of chronic infection , 2021, Nature.

[2] V. Simon,et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine , 2021, The New England journal of medicine.

[3] J. Absalon,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply. , 2021, The New England journal of medicine.

[4] M. Wills,et al. Age-related heterogeneity in Neutralising antibody responses to SARS-CoV-2 following BNT162b2 vaccination , 2021, medRxiv.

[5] M. Malim,et al. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike , 2021, bioRxiv.

[6] A. Coolen,et al. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients , 2021, Cancer Cell.

[7] Carl A. B. Pearson,et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[8] P. Dormitzer,et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans , 2020, medRxiv.

[9] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[10] S. Rowland-Jones,et al. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020) , 2020, Frontiers in Immunology.

[11] N. E. Babady,et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer , 2020, The New England journal of medicine.

[12] Gaurav D. Gaiha,et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.

[13] E. Fischer,et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.

[14] W. Wood,et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients , 2020, Blood.

[15] M. Malim,et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.

[16] P. Dormitzer,et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[17] J. Mason,et al. A dynamic COVID-19 immune signature includes associations with poor prognosis , 2020, Nature Medicine.

[18] X. Cui,et al. COVID-19 in cancer patients: risk, clinical features, and management , 2020, Cancer biology & medicine.

[19] G. Corrao,et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study , 2020, The Lancet Haematology.

[20] D. Barouch,et al. Approaches and Challenges in SARS-CoV-2 Vaccine Development , 2020, Cell Host & Microbe.

[21] U. Reimer,et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[22] M. Di Maio,et al. Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak , 2020, European journal of clinical investigation.

[23] M. Malim,et al. Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings , 2020, medRxiv.

[24] R. Germain,et al. Immune regulation by glucocorticoids can be linked to cell type–dependent transcriptional responses , 2019, The Journal of experimental medicine.

[25] P. Chyou,et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. , 2005, Clinical medicine & research.

[26] R. Couch,et al. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy , 1993, European Journal of Clinical Microbiology and Infectious Diseases.

[27] I. Aaberge,et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae , 2002, Medical oncology.